119 related articles for article (PubMed ID: 37716223)
1. Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival.
Marsh LA; Kim TH; Zhang M; Kubalanza K; Treece CL; Chase D; Memarzadeh S; Salani R; Karlan B; Rao J; Konecny GE
Gynecol Oncol; 2023 Oct; 177():173-179. PubMed ID: 37716223
[TBL] [Abstract][Full Text] [Related]
2. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.
Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A
Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067
[TBL] [Abstract][Full Text] [Related]
3. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
Cohen PA; Powell A; Böhm S; Gilks CB; Stewart CJR; Meniawy TM; Bulsara M; Avril S; Brockbank EC; Bosse T; de Azevedo Focchi GR; Ganesan R; Glasspool RM; Howitt BE; Kim HS; Lee JY; Le ND; Lockley M; Manchanda R; Mandalia T; McCluggage WG; McNeish I; Midha D; Srinivasan R; Tan YY; van der Griend R; Yunokawa M; Zannoni GF; ; Singh N
Gynecol Oncol; 2019 Aug; 154(2):441-448. PubMed ID: 31118141
[TBL] [Abstract][Full Text] [Related]
4. Response evaluation after neoadjuvant therapy: evaluation of chemotherapy response score and serological and/or radiological assessment of response in ovarian cancer patients.
Ramspott JP; Baert T; MacKintosh ML; Traut A; Ataseven B; Bommert M; Heitz F; Plett H; Schneider S; Waltering KU; Heikaus S; Harter P; du Bois A
Arch Gynecol Obstet; 2021 Oct; 304(4):1021-1032. PubMed ID: 33661392
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy.
Liontos M; Andrikopoulou A; Koutsoukos K; Markellos C; Skafida E; Fiste O; Kaparelou M; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Zagouri F
J Ovarian Res; 2021 Nov; 14(1):148. PubMed ID: 34724958
[TBL] [Abstract][Full Text] [Related]
6. A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant?
Lawson BC; Euscher ED; Bassett RL; Liu J; Ramalingam P; Zhong Y; Fleming ND; Malpica A
Am J Surg Pathol; 2020 Feb; 44(2):206-213. PubMed ID: 31651523
[TBL] [Abstract][Full Text] [Related]
7. Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy.
Liontos M; Sotiropoulou M; Kaparelou M; Tzannis K; Tsironis G; Kyriazoglou A; Tsiara A; Zakopoulou R; Koutsoukos K; Zagouri F; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Bamias A
Gynecol Oncol; 2020 Jun; 157(3):599-605. PubMed ID: 32173048
[TBL] [Abstract][Full Text] [Related]
8. Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations.
Barrington DA; Felix AS; Owda R; Suarez AA; Cohen DW; Senter L; Copeland LJ; Fowler JM; Backes FJ; Cohn DE; Bixel KL; O'Malley DM; Salani R; Cosgrove CM
Surg Oncol; 2020 Sep; 34():40-45. PubMed ID: 32891351
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy response score as a prognostic tool in patients with advanced stage endometrial carcinoma treated with neoadjuvant chemotherapy.
Jani I; Lastra RR; Brito KS; Liao C; Lazo I; Lee NK; Yamada SD; Kurnit KC
Int J Gynecol Cancer; 2021 Jun; 31(6):852-858. PubMed ID: 33833085
[TBL] [Abstract][Full Text] [Related]
10. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
11. Effects of neoadjuvant hyperthermic intraperitoneal chemotherapy on chemotherapy response score and recurrence in high-grade serous ovarian cancer patients with advanced disease: A multicentre retrospective cohort study.
Wu MF; Liang JX; Li H; Ye YF; Liang WF; Wang LJ; Zhang BZ; Chen Q; Lin ZQ; Li J
BJOG; 2022 Nov; 129 Suppl 2():5-13. PubMed ID: 36485072
[TBL] [Abstract][Full Text] [Related]
12. Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results.
Böhm S; Le N; Lockley M; Brockbank E; Faruqi A; Said I; Jeyarajah A; Wuntakal R; Gilks B; Singh N
Int J Gynecol Cancer; 2019 Feb; 29(2):353-356. PubMed ID: 30683759
[TBL] [Abstract][Full Text] [Related]
13. The added value of CA125 normalization before interval debulking surgery to the chemotherapy response score for the prognostication of ovarian cancer patients receiving neoadjuvant chemotherapy for advanced disease.
Liang WF; Wang LJ; Li H; Liu CH; Wu MF; Li J
J Cancer; 2021; 12(3):946-953. PubMed ID: 33403051
[No Abstract] [Full Text] [Related]
14. Prognostic Value of Pathologic Chemotherapy Response Score in Patients With Ovarian Cancer After Neoadjuvant Chemotherapy.
Michaan N; Chong WY; Han NY; Lim MC; Park SY
Int J Gynecol Cancer; 2018 Nov; 28(9):1676-1682. PubMed ID: 30256239
[TBL] [Abstract][Full Text] [Related]
15. Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer.
Nitecki R; Fleming ND; Fellman BM; Meyer LA; Sood AK; Lu KH; Rauh-Hain JA
Gynecol Oncol; 2021 Jun; 161(3):660-667. PubMed ID: 33867146
[TBL] [Abstract][Full Text] [Related]
16. Identification of Ovarian Cancer Patients Most Likely to Achieve Chemotherapy Response Score 3 Following Neoadjuvant Chemotherapy: Development of a Predictive Nomogram.
Liang WF; Li H; Wu JY; Liu CH; Wu MF; Li J
Front Oncol; 2020; 10():560888. PubMed ID: 33123471
[No Abstract] [Full Text] [Related]
17. Survival and Surgical Approach among Women with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy.
Persenaire C; Pyrzak A; Barber EL
J Minim Invasive Gynecol; 2022 Mar; 29(3):375-384. PubMed ID: 34648931
[TBL] [Abstract][Full Text] [Related]
18. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP
Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
Böhm S; Faruqi A; Said I; Lockley M; Brockbank E; Jeyarajah A; Fitzpatrick A; Ennis D; Dowe T; Santos JL; Cook LS; Tinker AV; Le ND; Gilks CB; Singh N
J Clin Oncol; 2015 Aug; 33(22):2457-63. PubMed ID: 26124480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
